arrow
U

Ulrich Jäger

Medical University of Vienna
H指数:57
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia

DUSP1是毛细胞白血病中疾病持续存在的关键驱动因素和潜在治疗靶点

2026-05-280
OAAI
Changes in cardiac parameters during venetoclax treatment

在venetoclax治疗期间的心脏参数变化

2025-10-010
OAAI
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe

欧洲接受CAR T细胞疗法治疗的血液恶性肿瘤患者的患者报告结局

2025-09-260
OAAI
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

评估接受tisagenlecleucel治疗的复发/难治性B-ALL和DLBCL患者体内CAR转座子水平的评价

2025-06-260
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study (JUL, 10.1038/s41591-024-02986-9, 2024)
2024-07-094
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
2024-06-039
OAAI
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

淋巴细胞耗竭-嵌合抗原受体T细胞治疗周期的重要但被低估的部分

2023-12-2229
OAAI
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
2023-10-1327
OAAI
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2023-05-3046
OAAI
The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma

分化的CD3 CD27-CD28 T细胞的频率可预测弥漫性大b细胞淋巴瘤对CART细胞治疗的反应

2023-01-0914
OAAI
N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
2023-01-014
OAAI
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

血液学2021中的精准医学: 定义、工具、观点和开放性问题

2021-03-017
OAAI